Compounding Problems: Recent Decisions on Tirzepatide Highlight Interplay Between FDA Anti-Compounding Enforcement and Private Intellectual Property Rights
Earlier this month, a federal district court denied the Outsourcing Facilities Association’s preliminary injunction motion, which sought to preclude FDA from taking enforcement action against compounded tirzepatide products.[1]
Axinn Associates at the Antitrust Spring Meeting
During the Spring Meeting, Axinn associates attended thought leadership panels to capture key insights. Read their takeaways from the panels.
Brand Building and Buy-In: How a Strong Brand Can Drive Law Firm Growth
Axinn chief marketing & business development officer Julie Chodos co-authored “Brand Building and Buy-In: How a Strong Brand Can Drive Law Firm Growth,” with Judith McKay of JEM3 Consulting, which appeared on Law.com.
Compounding Problems: Recent Decisions on Tirzepatide Highlight Interplay Between FDA Anti-Compounding Enforcement and Private Intellectual Property Rights
Earlier this month, a federal district court denied the Outsourcing Facilities Association’s preliminary injunction motion, which sought to preclude FDA from taking enforcement action against compounded tirzepatide products.[1]
Axinn Associates at the Antitrust Spring Meeting
During the Spring Meeting, Axinn associates attended thought leadership panels to capture key insights. Read their takeaways from the panels.
Brand Building and Buy-In: How a Strong Brand Can Drive Law Firm Growth
Axinn chief marketing & business development officer Julie Chodos co-authored “Brand Building and Buy-In: How a Strong Brand Can Drive Law Firm Growth,” with Judith McKay of JEM3 Consulting, which appeared on Law.com.
Compounding Problems: Recent Decisions on Tirzepatide Highlight Interplay Between FDA Anti-Compounding Enforcement and Private Intellectual Property Rights
Earlier this month, a federal district court denied the Outsourcing Facilities Association’s preliminary injunction motion, which sought to preclude FDA from taking enforcement action against compounded tirzepatide products.[1]
Insights
